Increased Cellular Invasion and Proliferation via Estrogen Receptor after 17-β-Estradiol Treatment in Breast Cancer Cells Using Stable Isotopic Labeling with Amino Acids in Cell Culture (SILAC)

Alimatou M. Tchafa, Zhijiu Zhong, Rong Meng, Judy N. Quong, Andrew A. Quong

American Association of Cancer Research, Philadelphia, USA.
Department of Biomedical Engineering, Drexel University, Philadelphia, USA.
Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, USA.

DOI: 10.4236/abcr.2013.22007                

Abstract

17-β-estradiol (estrogen) is a steroid hormone important to human development; however, high levels of this molecule are associated with increased risk of breast cancer primarily due to estrogen’s ability to bind and activate the estrogen receptor (ER) and initiate gene transcription. Currently, estrogen mechanisms of action are classified as genomic and non-genomic and occur in an ER-dependent and ER-independent manner. In this study, we examine estrogen signaling pathways, by measuring changes in protein expression as a function of time of exposure to estrogen in both ER-positive (MCF-7) and ER-negative (MDA-MB-231) cell lines. Using a robust experimental design utilizing isotopic labeling, two-dimensional LC-MS, and bioinformatics analysis, we report genomic and non-genomic ER regulated estrogen responsive proteins. We find a little over 200 proteins differentially expressed after estrogen treatment. Cell proliferation, transcription, actin filament capping and cell to cell signaling are significantly enriched in the MCF-7 cell line alone. Translational elongation and proteolysis are enriched in both cell lines. Subsets of the proteins presented in this study are for the first time directly associated with estrogen signaling in mammary carcinoma cells. We find that estrogen affected the expression of proteins involved in numerous processes that are related to tumorigenesis such as increased cellular division and invasion in an ER-dependent manner. Moreover, we identified negative regulation of apoptosis as a non-genomic process of estrogen. This study complements gene expression studies and highlights the need for both genomic and proteomic analyses in unraveling the complex mechanisms by which estrogen affects progression of breast cancer.

Keywords

17-β-Estradiol; Breast Cancer; Estrogen Receptor; Mass Spectrometry; SILAC

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	D. T. Baird and I. S. Fraser, “Blood Production and Ovarian Secretion Rates of Estradiol 17β and Estrone in Women throughout the Menstrual Cycle,” Journal of Clinical Endocrinology and Metabolism, Vol. 38, No. 6, 1974, pp. 1009-1017. doi:10.1210/jcem-38-6-1009
[2]	C. Flood, J. H. Pratt and C. Longcope, “The Metabolic Clearance and Blood Production Rates of Estriol in Normal, Non Pregnant Women,” Journal of Clinical Endocrinology and Metabolism, Vol. 42, No. 1, 1976, pp. 1-8. doi:10.1210/jcem-42-1-1
[3]	J. G. Liehr, “Is Estradiol a Genotoxic Mutagenic Carcinogen?” Endocrine Reviews, Vol. 21, No. 1, 2000, pp. 40-54. doi:10.1210/er.21.1.40
[4]	C. J. Gruber, et al., “Mechanisms of Disease: Production and Actions of Estrogens,” New England Journal of Medicine, Vol. 346, No. 5, 2002, pp. 340-352. doi:10.1056/NEJMra000471
[5]	B. W. O’Malley, et al., “Studies on the Mechanism of Steroid Hormone Regulation of Synthesis of Specific Proteins,” Recent Progress in Hormone Research, Vol. 25, 1969, pp. 105-160.
[6]	W. Wang, et al., “Transcriptional Activation of E2F1 Gene Expression by 17β-Estradiol in MCF-7 Cells Is Regulated by NF-Y-Sp1/Estrogen Receptor Interactions,” Molecular Endocrinology, Vol. 13, No. 8, 1999, pp. 1373-1387. doi:10.1210/me.13.8.1373
[7]	Y. Umayahara, et al., “Estrogen Regulation of the Insulin-Like Growth Factor I Gene Transcription Involves an AP-1 Enhancer,” Journal of Biological Chemistry, Vol. 269, No. 23, 1994, pp. 16433-16442.
[8]	K. T. Lim, et al., “Nongenomic Oestrogen Signalling in Oestrogen Receptor Negative Breast Cancer Cells: A Role for the Angiotensin II Receptor AT1,” Breast Cancer Research, Vol. 8, No. 3, 2006, p. R33. doi:10.1186/bcr1509
[9]	T. Improta-Brears, et al., “Estrogen-Induced Activation of Mitogen-Activated Protein Kinase Requires Mobilization of Intracellular Calcium,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 96, No. 8, 1994, pp. 4686-4691. doi:10.1073/pnas.96.8.4686
[10]	D. A. Zajchowski, R. Sager and L. Webster, “Estrogen Inhibits the Growth of Estrogen Receptor-Negative, but Not Estrogen Receptor-Positive, Human Mammary Epithelial Cells Expressing a Recombinant Estrogen Receptor,” Cancer Research, Vol. 53, No. 20, 1993, pp. 5004-5011.
[11]	F. Gadal, et al., “Integrative Analysis of Gene Expression Patterns Predicts Specific Modulations of Defined Cell Functions by Estrogen and Tamoxifen in MCF7 Breast Cancer Cells,” Journal of Molecular Endocrinology, Vol. 34, No. 1, 2005, pp. 61-75. doi:10.1677/jme.1.01631
[12]	A. Inoue, et al., “Development of cDNA Microarray for Expression Profiling of Estrogen-Responsive Genes,” Journal of Molecular Endocrinology, Vol. 29, No. 2, 2002, pp. 175-192. doi:10.1677/jme.0.0290175
[13]	J. Frasor, et al., “Profiling of Estrogen Upand DownRegulated Gene Expression in Human Breast Cancer Cells: Insights into Gene Networks and Pathways Underlying Estrogenic Control of Proliferation and Cell Phenotype,” Endocrinology, Vol. 144, No. 10, 2003, pp. 4562-4574. doi:10.1677/jme.0.0290175
[14]	H. Watanabe, et al., “Genome-Wide Analysis of Changes in Early Gene Expression Induced by Oestrogen,” Genes to Cells, Vol. 7, No. 5, 2002, pp. 497-507. doi:10.1046/j.1365-2443.2002.00535.x
[15]	K. R. Coser, et al., “Global Analysis of Ligand Sensitivity of Estrogen Inducible and Suppressible Genes in MCF7/ BUS Breast Cancer Cells by DNA Microarray,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 100, Suppl. 2, 2003, pp. 13994-13999. doi:10.1073/pnas.2235866100
[16]	A. M. Soto and C. Sonnenschein, “Mechanism of Estrogen Action on Cellular Proliferation: Evidence from Indirect and Negative Control on Cloned Breast Tumor Cells,” Biochemical and Biophysical Research Communications, Vol. 122, No. 3, 1984, pp. 1097-1103. doi:10.1016/0006-291X(84)91204-X
[17]	J. T. Papendorp, et al., “On the Role of 17 Alpha-Estradiol and 17 Beta-Estradiol in the Proliferation of MCF7 and T47D-A11 Human Breast Tumor Cells,” Journal of Cellular Physiology, Vol. 125, No. 3, 1985, pp. 591-595. doi:10.1002/jcp.1041250331
[18]	S. Tang, et al., “Computational Method for Discovery of Estrogen Responsive Genes,” Nucleic Acids Research, Vol. 325, No. 21, 2004, pp. 6212-6217. doi:10.1093/nar/gkh943
[19]	S. Tang, et al., “KBERG: Knowledge Base for Estrogen Responsive Genes,” Nucleic Acids Research, Vol. 35, Suppl. 1, 2007, pp. D732-736.
[20]	D. Y. Wang, et al., “Identification of Estrogen-Responsive Genes by Complementary Deoxyribonucleic Acid Microarray and Characterization of a Novel Early Estrogen-Induced Gene: EEIG1,” Molecular Endocrinology, Vol. 18, No. 2, 2004, pp. 402-411. doi:10.1210/me.2003-0202
[21]	C. J. Creighton, et al., “Genes Regulated by Estrogen in Breast Tumor Cells in Vitro Are Similarly Regulated in Vivo in Tumor Xenografts and Human Breast Tumors,” Genome Biology, Vol. 7, No. 4, 2006, p. R28. doi:10.1186/gb-2006-7-4-r28
[22]	J. Zhao, et al., “Proteomic Analysis of Estrogen Response of Premalignant Human Breast Cells Using a 2-D Liquid Separation/Mass Mapping Technique,” Proteomics, Vol. 6, No. 13, 2006, pp. 3847-3861. doi:10.1002/pmic.200500195
[23]	J. M. Armenta, I. Hoeschele and I. M. Lazar, “Differential Protein Expression Analysis Using Stable Isotope Labeling and PQD Linear Ion Trap MS Technology,” Journal of the American Society for Mass Spectrometry, Vol. 20, No. 7, 2009, pp. 1287-1302. doi:10.1016/j.jasms.2009.02.029
[24]	L. Malorni, et al., “Proteomic Analysis of MCF-7 Breast Cancer Cell Line Exposed to Mitogenic Concentration of 17β-Estradiol,” Proteomics, Vol. 6, No. 22, 2006, pp. 5973-5982. doi:10.1002/pmic. 200600333
[25]	Z. Zhu, A. R. Boobis and R. J. Edwards, “Identification of Estrogen-Responsive Proteins in MCF-7 Human Breast Cancer Cells Using Label-Free Quantitative Proteomics,” Proteomics, Vol. 8, No. 10, 2008, pp. 1987-2005. doi:10.1002/pmic.200700901
[26]	Z. Zhu, R. J. Edwards and A. R. Boobis, “Increased Expression of Histone Proteins during Estrogen-Mediated Cell Proliferation,” Environmental Health Perspectives, Vol. 117, No. 6, 2009, pp. 928-934.
[27]	S. E. Ong, et al., “Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics,” Molecular & Cellular Proteomics: MCP, Vol. 1, No. 5, 2002, pp. 376-386. doi:10.1074/mcp.M200025-MCP200
[28]	S. C. Bendall, et al., “Prevention of Amino Acid Conversion in SILAC Experiments with Embryonic Stem Cells,” Molecular and Cellular Proteomics, Vol. 7, No. 9, 2008, pp. 1587-1597. doi:10.1074/mcp. M800113-MCP200
[29]	R. T. Schumacher, et al., “An Automated Sample Preparation Solution for Nucleic Acid and Protein Extraction from Cells and Tissues,” American Laboratory, Vol. 34, No. 16, 2002, p. 38.
[30]	X. J. Li, et al., “Automated Statistical Analysis of Protein Abundance Ratios from Data Generated by Stable-Isotope Dilution and Tandem Mass Spectrometry,” Analytical Chemistry, Vol. 75, No. 123, 2003, pp. 6648-6657. doi:10.1021/ac034633i
[31]	G. Dennis Jr., et al., “DAVID: Database for Annotation, Visualization, and Integrated Discovery,” Genome Biology, Vol. 4, No. 5, 2003, p. P3. doi:10.1186/gb-2003-4-5-p3
[32]	D. W. Huang, B. T. Sherman and R. A. Lempicki, “Systematic and Integrative Analysis of Large Gene Lists Using DAVID Bioinformatics Resources,” Nature Protocols, Vol. 4, No. 1, 2009, pp. 44-57. doi:10.1038/nprot.2008.211
[33]	H. Nawata, et al., “Estradiol-Independent Growth of a Subline of MCF-7 Human Breast Cancer Cells in Culture,” Journal of Biological Chemistry, Vol. 256, No. 13, 1981, pp. 6895-6902.
[34]	B. Manavathi, et al., “An Inherent Role of Microtubule Network in the Action of Nuclear Receptor,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 43, 2006, pp. 15981-15986. doi:10.1073/pnas.0607445103
[35]	U. Banerji, “Heat Shock Protein 90 as a Drug Target: Some Like It Hot,” Clinical Cancer Research, Vol. 15, No. 1, 2009, pp. 9-14. doi:10.1158/1078-0432.CCR-08-0132
[36]	T. C. Skaar, et al., “Two-Dimensional Gel Electrophoresis Analyses Identify Nucleophosmin as an Estrogen Regulated Protein Associated with Acquired Estrogen-Independence in Human Breast Cancer Cells,” Journal of Steroid Biochemistry and Molecular Biology, Vol. 67, No. 5-6, 1998, pp. 391-402. doi:10.1016/S0960-0760(98)00142-3
[37]	S. Khurana, et al., “The Actin-Binding Protein, Actinin Alpha 4 (ACTN4), Is a Nuclear Receptor Coactivator That Promotes Proliferation of MCF-7 Breast Cancer Cells,” The Journal of Biological Chemistry, Vol. 286, No. 3, 2010, pp. 1850-1859.
[38]	G. Odabaei, et al., “Raf-1 Kinase Inhibitor Protein: Structure, Function, Regulation of Cell Signaling, and Pivotal Role in Apoptosis,” Advances in Cancer Research, Vol. 94, 2004, pp. 169-200.
[39]	K. Yeung, et al., “Suppression of Raf-1 Kinase Activity and MAP Kinase Signalling by RKIP,” Nature, Vol. 401, No. 6749, 1999, pp. 173-177. doi:10.1038/43686
[40]	D. Nagakubo, et al., “DJ-1, a Novel Oncogene Which Transforms Mouse NIH3T3 Cells in Cooperation with ras,” Biochemical and Biophysical Research Communications, Vol. 231, No. 2, 1997. pp. 509-513. doi:10.1006/bbrc.1997.6132
[41]	R. H. Kim, et al., “DJ-1, a Novel Regulator of the Tumor Suppressor PTEN,” Cancer Cell, Vol. 7, No. 3, 2005, pp. 263-273. doi:10.1016/j.ccr.2005.02.010
[42]	Y. Huang, et al., “The Angiogenic Function of Nucleolin Is Mediated by Vascular Endothelial Growth Factor and Nonmuscle Myosin,” Blood, Vol. 107, No. 9, 2006, pp. 3564-3571. doi:10.1182/blood-2005-07-2961
[43]	S. Soundararajan, et al., “The Nucleolin Targeting Aptamer AS1411 Destabilizes Bcl-2 Messenger RNA in Human Breast Cancer Cells,” Cancer Research, Vol. 68, No. 7, 2008, pp. 2358-2365. doi:10.1158/0008-5472.CAN-07-5723
[44]	J. M. Cuezva, et al., “The Biogenetic Signature of Cancer: A Marker of Tumor Progression,” Cancer Research, Vol. 62, No. 22, 2002, pp. 6674-6681.
[45]	I. M. Willers, et al., “Selective Inhibition of β-F1-ATPase mRNA Translation in Human Tumours,” Biochemical Journal, Vol. 426, No. 3, 2010, pp. 319-326. doi:10.1042/BJ20091570
[46]	D. R. Littler, et al., “The Intracellular Chloride Ion Channel Protein CLIC1 Undergoes a Redox-controlled Structural Transition,” Journal of Biological Chemistry, Vol. 279, No. 10, 2004, pp. 9298-9305. doi:10.1074/jbc.M308444200
[47]	E. F. Rocnik, et al., “Functional Linkage Between the Endoplasmic Reticulum Protein Hsp47 and Procollagen Expression in Human Vascular Smooth Muscle Cells,” Journal of Biological Chemistry, Vol. 277, No. 41, 2002, pp. 38571-38578. doi:10.1074/jbc.M206689200
[48]	M. D. Welch, A. Iwamatsu and T. J. Mitchison, “Actin Polymerization Is Induced by Arp2/3 Protein Complex at the Surface of Listeria Monocytogenes,” Nature, Vol. 385, No. 6613, 1997, pp. 265-269. doi:10.1038/385265a0
[49]	Z. Wen, Z. Zhong and J. E. Darnell, “Maximal Activation of Transcription by Stat1 and Stat3 Requires Both Tyrosine and Serine Phosphorylation,” Cell, Vol. 82, No. 2, 1995, pp. 241-250. doi:10.1016/0092-8674(95)90311-9
[50]	J. A. Lavigne, et al., “The Effects of Catechol-O-Methyltransferase Inhibition on Estrogen Metabolite and Oxidative DNA Damage Levels in Estradiol-Treated MCF-7 Cells,” Cancer Research, Vol. 61, No. 20, 2001, pp. 7488-7494.
[51]	H. C. Guldberg and C. A. Marsden, “Catechol-O-Methyl Transferase: Pharmacological Aspects and Physiological Role,” Pharmacological Reviews, Vol. 27, No. 2, 1975, pp. 135-206.
[52]	L. C. Zacharia, et al., “2-Hydroxyestradiol Is a Prodrug of 2-Methoxyestradiol,” Journal of Pharmacology and Experimental Therapeutics, Vol. 309, No. 3, 2004, pp. 1093-1097. doi:10.1124/jpet. 103.062505
[53]	J. Kassis, et al., “Tumor Invasion as Dysregulated Cell Motility,” Seminars in Cancer Biology, Vol. 11, No. 2, 2001, pp. 105-117. doi:10.1006/scbi.2000.0362
[54]	I. G. Wool, “Extraribosomal Functions of Ribosomal Proteins,” Trends in Biochemical Sciences, Vol. 21, No. 5, 1996, pp. 164-165.
[55]	R. Comitato, et al., “A Novel Mechanism of Natural Vitamin E Tocotrienol Activity: Involvement of ERβ Signal Transduction,” American Journal of Physiology—Endocrinology and Metabolism, Vol. 297, No. 2, 2009, pp. E427-E437. doi:10.1152/ajpendo.00187.2009
[56]	S. Mann, et al., “Estrogen Receptor Beta Expression in Invasive Breast Cancer,” Human Pathology, Vol. 3, No. 1, 2001, pp. 113-118. doi:10.1053/hupa.2001.21506
[57]	P. A. Everley, et al., “Enhanced Analysis of Metastatic Prostate Cancer Using Stable Isotopes and High Mass Accuracy Instrumentation,” Journal of Proteome Research, Vol. 5, No. 5, 2006, pp. 1224-1231. doi:10.1021/pr0504891
[58]	W. C. Merrick, “Mechanism and Regulation of Eukaryotic Protein Synthesis,” Microbiological Reviews, Vol. 56, No. 2, 1992, pp. 291-315.
[59]	E. R. Levin, “Integration of the Extranuclear and Nuclear Actions of Estrogen,” Molecular Endocrinology, Vol. 19, No. 8, 2005, pp. 1951-1959. doi:10.1210/me.2004-0390
[60]	R. X. D. Song and R. J. Santen, “Membrane Initiated Estrogen Signaling in Breast Cancer,” Biology of Reproduction, Vol. 75, No. 1, 2006, pp. 9-16. doi:10.1095/biolreprod.105.050070